BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(30 sites)
United States
Southern Cancer Center, Daphne, Alabama Sansum Clinic, Santa Barbara, California Florida Cancer Specialists - South, Fort Myers, Florida University of Miami - Sylvester Cancer Center, Miami, Florida Ocala Oncology Center, Ocala, Florida Florida Cancer Specialists - North, Orange City, Florida Cancer Care Centers of Brevard, Palm Bay, Florida Florida Cancer Specialists - East, West Palm Beach, Florida Illinois Cancer Specialists, Arlington Heights, Illinois Illinois Cancer Care, Peoria, Illinois Indiana University Simon Cancer Center, Indianapolis, Indiana Baptist Health - Lexington, Lexington, Kentucky Baptist Health - Louisville, Louisville, Kentucky Minnesota Oncology Hematology, Maple Grove, Minnesota Missouri Cancer Associates, Columbia, Missouri White Plains Hospital Physician Associates, White Plains, New York Oncology Hematology Care, Cincinnati, Ohio Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center, Columbus, Ohio Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center), Eugene, Oregon Tennessee Cancer Specialists, Knoxville, Tennessee SCRI Oncology Partners, Nashville, Tennessee Texas Oncology - West Texas, Amarillo, Texas Texas Oncology- Austin, Austin, Texas Texas Oncology - Gulf Coast, Beaumont, Texas Texas Oncology - DFW, Dallas, Texas Texas Oncology - Northeast Texas, Denison, Texas Texas Oncology - San Antonio, San Antonio, Texas Virginia Cancer Specialists, Fairfax, Virginia Virginia Oncology Associates, Norfolk, Virginia Blue Ridge Cancer Center (Oncology & Hematology Associates of Southwest VA), Salem, Virginia Last updated February 2026